be0298 Search Results


anti-tmb1 bioxcell (catalog number be0298)  (Bio X Cell)
90
Bio X Cell anti-tmb1 bioxcell (catalog number be0298)
H89 mediates immunotherapeutic activity against colon cancer. (A, B) CT26 or C51 tumor-bearing BALB/c mice (5 × 10 5 murine colon cancer cells in s.c.) were treated, or not <t>(NaCl,</t> i.p.), with H89 (10 mg/kg, i.p.) twice a week, and tumor growth was monitored three times a week ( A , n = 10 mice/group; B , n = 7 mice/group). (C) Oral administration of H89 (5 mg/kg), or NaCl in the control group, twice a week in CT26 tumor-bearing BALB/c mice. Tumor growth was monitored three times a week ( n = 7 mice/group). (D) 4T1 breast cancer cells tumor-bearing mice (5 × 10 5 4T1 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (5 mg/kg, i.p.) twice a week, and tumor growth was monitored three times a week ( n = 5 mice/group). (E) CT26 tumor-bearing BALB/c mice (5 × 10 5 CT26 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week, in combination with 5-fluorouracil (5-FU, 5 mg/kg in i.p.) once a week, and tumor growth was monitored three times a week ( n = 14 mice/group). (F) Swiss nude immunodeficient mice, bearing CT26 tumors (5 × 10 5 CT26 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week, and tumor growth was monitored three times a week ( n = 5 mice/group). (G) CT26 tumor-bearing BALB/c mice (5 × 10 5 CT26 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week. Mice also received anti-CD8a or control IgG injections once a week (500 µg in i.p.), and tumor growth was monitored three times a week ( n = 7 mice/group). Statistically significant differences were determined by using two-way ANOVA: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; n.s., nonsignificant results.
Anti Tmb1 Bioxcell (Catalog Number Be0298), supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-tmb1 bioxcell (catalog number be0298)/product/Bio X Cell
Average 90 stars, based on 1 article reviews
anti-tmb1 bioxcell (catalog number be0298) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


H89 mediates immunotherapeutic activity against colon cancer. (A, B) CT26 or C51 tumor-bearing BALB/c mice (5 × 10 5 murine colon cancer cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week, and tumor growth was monitored three times a week ( A , n = 10 mice/group; B , n = 7 mice/group). (C) Oral administration of H89 (5 mg/kg), or NaCl in the control group, twice a week in CT26 tumor-bearing BALB/c mice. Tumor growth was monitored three times a week ( n = 7 mice/group). (D) 4T1 breast cancer cells tumor-bearing mice (5 × 10 5 4T1 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (5 mg/kg, i.p.) twice a week, and tumor growth was monitored three times a week ( n = 5 mice/group). (E) CT26 tumor-bearing BALB/c mice (5 × 10 5 CT26 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week, in combination with 5-fluorouracil (5-FU, 5 mg/kg in i.p.) once a week, and tumor growth was monitored three times a week ( n = 14 mice/group). (F) Swiss nude immunodeficient mice, bearing CT26 tumors (5 × 10 5 CT26 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week, and tumor growth was monitored three times a week ( n = 5 mice/group). (G) CT26 tumor-bearing BALB/c mice (5 × 10 5 CT26 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week. Mice also received anti-CD8a or control IgG injections once a week (500 µg in i.p.), and tumor growth was monitored three times a week ( n = 7 mice/group). Statistically significant differences were determined by using two-way ANOVA: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; n.s., nonsignificant results.

Journal: Frontiers in Immunology

Article Title: Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer

doi: 10.3389/fimmu.2022.875764

Figure Lengend Snippet: H89 mediates immunotherapeutic activity against colon cancer. (A, B) CT26 or C51 tumor-bearing BALB/c mice (5 × 10 5 murine colon cancer cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week, and tumor growth was monitored three times a week ( A , n = 10 mice/group; B , n = 7 mice/group). (C) Oral administration of H89 (5 mg/kg), or NaCl in the control group, twice a week in CT26 tumor-bearing BALB/c mice. Tumor growth was monitored three times a week ( n = 7 mice/group). (D) 4T1 breast cancer cells tumor-bearing mice (5 × 10 5 4T1 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (5 mg/kg, i.p.) twice a week, and tumor growth was monitored three times a week ( n = 5 mice/group). (E) CT26 tumor-bearing BALB/c mice (5 × 10 5 CT26 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week, in combination with 5-fluorouracil (5-FU, 5 mg/kg in i.p.) once a week, and tumor growth was monitored three times a week ( n = 14 mice/group). (F) Swiss nude immunodeficient mice, bearing CT26 tumors (5 × 10 5 CT26 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week, and tumor growth was monitored three times a week ( n = 5 mice/group). (G) CT26 tumor-bearing BALB/c mice (5 × 10 5 CT26 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week. Mice also received anti-CD8a or control IgG injections once a week (500 µg in i.p.), and tumor growth was monitored three times a week ( n = 7 mice/group). Statistically significant differences were determined by using two-way ANOVA: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; n.s., nonsignificant results.

Article Snippet: For IL-15RA blockade, an anti-TMB1 (BioXCell (catalog number BE0298) 50 μg in 100 μl of NaCl) or IgG2A control isotype (BioXCell 50 μg in 100 μl of NaCl) was injected (i.p.) the day before the first H89 administration and renewed twice a week.

Techniques: Activity Assay, Control

H89 regulates signaling pathways involved in immune cell activation and cancer cell growth. (A) RNAseq analysis were performed on CT26 solid tumors isolated from BALB/c mice treated or not (NaCl) with H89 (10 mg/kg, i.p.) at D14 after colon cancer cells injection ( n = 3 mice/group). (B) RT-qPCR analysis of IL-15 expression mRNA level at D14 and D21 after CT26 cancer cell injection into BALB/c mice ( n = 3 mice/group) and ELISA analysis of IL-15 on tumor lysates ad D14 ( n = 5 mice/group). (C) RT-qPCR analysis of IL-15 expression mRNA level on CT26 cells treated in vitro with H89 for 24 h ( n = 3). (D) CT26 tumor-bearing BALB/c mice (5 × 10 5 CT26 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week. Mice also received anti-TMB1 or control IgG injections once a week (50 µg in i.p.), and tumor growth was monitored three times a week ( n = 7 mice/group). (E–G) Western blot analysis of Akt phosphorylation (P-Akt) after H89 treatment in CD8 T cells isolated from the spleen of BALB/c mice or MOLT-4 and Jurkat T cells ( n = 5) (H, I) Quantification of the enzymatic activity of phosphatase PP2A in Jurkat and MOLT-4 T cells ( n = 3). Statistically significant differences were determined by using two-way ANOVA (D) or a t -test (B , C , E – I) : * p ≤ 0.05 (or 0.1 in (B) with 90% confidence level); ** p ≤ 0.01; *** p ≤ 0.001; n.s., nonsignificant results. RNAseq analysis was performed with the DESeq2 package using a Wald test.

Journal: Frontiers in Immunology

Article Title: Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer

doi: 10.3389/fimmu.2022.875764

Figure Lengend Snippet: H89 regulates signaling pathways involved in immune cell activation and cancer cell growth. (A) RNAseq analysis were performed on CT26 solid tumors isolated from BALB/c mice treated or not (NaCl) with H89 (10 mg/kg, i.p.) at D14 after colon cancer cells injection ( n = 3 mice/group). (B) RT-qPCR analysis of IL-15 expression mRNA level at D14 and D21 after CT26 cancer cell injection into BALB/c mice ( n = 3 mice/group) and ELISA analysis of IL-15 on tumor lysates ad D14 ( n = 5 mice/group). (C) RT-qPCR analysis of IL-15 expression mRNA level on CT26 cells treated in vitro with H89 for 24 h ( n = 3). (D) CT26 tumor-bearing BALB/c mice (5 × 10 5 CT26 cells in s.c.) were treated, or not (NaCl, i.p.), with H89 (10 mg/kg, i.p.) twice a week. Mice also received anti-TMB1 or control IgG injections once a week (50 µg in i.p.), and tumor growth was monitored three times a week ( n = 7 mice/group). (E–G) Western blot analysis of Akt phosphorylation (P-Akt) after H89 treatment in CD8 T cells isolated from the spleen of BALB/c mice or MOLT-4 and Jurkat T cells ( n = 5) (H, I) Quantification of the enzymatic activity of phosphatase PP2A in Jurkat and MOLT-4 T cells ( n = 3). Statistically significant differences were determined by using two-way ANOVA (D) or a t -test (B , C , E – I) : * p ≤ 0.05 (or 0.1 in (B) with 90% confidence level); ** p ≤ 0.01; *** p ≤ 0.001; n.s., nonsignificant results. RNAseq analysis was performed with the DESeq2 package using a Wald test.

Article Snippet: For IL-15RA blockade, an anti-TMB1 (BioXCell (catalog number BE0298) 50 μg in 100 μl of NaCl) or IgG2A control isotype (BioXCell 50 μg in 100 μl of NaCl) was injected (i.p.) the day before the first H89 administration and renewed twice a week.

Techniques: Protein-Protein interactions, Activation Assay, Isolation, Injection, Quantitative RT-PCR, Expressing, Enzyme-linked Immunosorbent Assay, In Vitro, Control, Western Blot, Phospho-proteomics, Activity Assay